» Articles » PMID: 23445698

Dyspnea in Chronic Fatigue Syndrome (CFS): Comparison of Two Prospective Cross-sectional Studies

Overview
Date 2013 Mar 1
PMID 23445698
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic Fatigue Syndrome (CFS) subjects have many systemic complaints including shortness of breath. Dyspnea was compared in two CFS and control cohorts to characterize pathophysiology. Cohort 1 of 257 CFS and 456 control subjects were compared using the Medical Research Council chronic Dyspnea Scale (MRC Score; range 0-5). Cohort 2 of 106 CFS and 90 controls answered a Dyspnea Severity Score (range 0-20) adapted from the MRC Score. Subsets of both cohorts completed CFS Severity Scores, fatigue, and other questionnaires. A subset had pulmonary function and total lung capacity measurements. Results show MRC Scores were equivalent between sexes in Cohort 1 CFS (1.92 [1.72-2.16]; mean [95% C.I.]) and controls (0.31 [0.23-0.39]; p<0.0001). Receiver-operator curves identified 2 as the threshold for positive MRC Scores in Cohort 1. This indicated 54% of CFS, but only 3% of controls, had significant dyspnea. In Cohort 2, Dyspnea Score threshold of 4 indicated shortness of breath in 67% of CFS and 23% of controls. Cohort 2 Dyspnea Scores were higher for CFS (7.80 [6.60-9.00]) than controls (2.40 [1.60-3.20]; p<0.0001). CFS had significantly worse fatigue and other complaints compared to controls. Pulmonary function was normal in CFS, but Borg scores and sensations of chest pain and dizziness were significantly greater during testing than controls. General linear model of Cohort 2 CFS responses linked Dyspnea with rapid heart rate, chest pain and dizziness. In conclusion, sensory hypersensitivity without airflow limitation contributed to dyspnea in CFS. Correlates of dyspnea in controls were distinct from CFS suggesting different mechanisms.

Citing Articles

Fatigue presentation, severity, and related outcomes in a prospective cohort following post-COVID-19 hospitalization in British Columbia, Canada.

Magel T, Meagher E, Boulter T, Albert A, Tsai M, Munoz C Front Med (Lausanne). 2023; 10:1179783.

PMID: 37457578 PMC: 10344448. DOI: 10.3389/fmed.2023.1179783.


Brainstem volume changes in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID patients.

Thapaliya K, Marshall-Gradisnik S, Barth M, Eaton-Fitch N, Barnden L Front Neurosci. 2023; 17:1125208.

PMID: 36937672 PMC: 10017877. DOI: 10.3389/fnins.2023.1125208.


Review of the Midbrain Ascending Arousal Network Nuclei and Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Gulf War Illness (GWI) and Postexertional Malaise (PEM).

Baraniuk J Brain Sci. 2022; 12(2).

PMID: 35203896 PMC: 8870178. DOI: 10.3390/brainsci12020132.


Informatics Inference of Exercise-Induced Modulation of Brain Pathways Based on Cerebrospinal Fluid Micro-RNAs in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Narayan V, Shivapurkar N, Baraniuk J Netw Syst Med. 2020; 3(1):142-158.

PMID: 33274349 PMC: 7703497. DOI: 10.1089/nsm.2019.0009.


Myalgic Encephalomyelitis: Symptoms and Biomarkers.

Jason L, Zinn M, Zinn M Curr Neuropharmacol. 2015; 13(5):701-34.

PMID: 26411464 PMC: 4761639. DOI: 10.2174/1570159x13666150928105725.

References
1.
Cook D, Nagelkirk P, Poluri A, Mores J, Natelson B . The influence of aerobic fitness and fibromyalgia on cardiorespiratory and perceptual responses to exercise in patients with chronic fatigue syndrome. Arthritis Rheum. 2006; 54(10):3351-62. DOI: 10.1002/art.22124. View

2.
Lurie M, Caidahl K, Johansson G, Bake B . Respiratory function in chronic primary fibromyalgia. Scand J Rehabil Med. 1990; 22(3):151-5. View

3.
Mukerji B, Mukerji V, Alpert M, Selukar R . The prevalence of rheumatologic disorders in patients with chest pain and angiographically normal coronary arteries. Angiology. 1995; 46(5):425-30. DOI: 10.1177/000331979504600510. View

4.
Weiss D, Kreck T, Albert R . Dyspnea resulting from fibromyalgia. Chest. 1998; 113(1):246-9. DOI: 10.1378/chest.113.1.246. View

5.
Gur A, Oktayoglu P . Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des. 2008; 14(13):1274-94. DOI: 10.2174/138161208799316348. View